Ross, TedRobinson, Harriet2019-11-112019-11-112003-03-20International Publication #WO2003022204A2US Pat# US28262101Phttp://hdl.handle.net/10342/7541The present invention provides a novel vaccine expressing a fusion of the measles hemagglutinin (H) protein and the complement component, C3d, to enhance the titers of neutralizing antibody. Plasmids were generated that expressed a secreted (s) form of H and the same form fused to three tandem copies of the murine homologue of C3d (sH-3C3d). Analysis of titers of the antibody raised in vaccinated mice indicated that groups vaccinated with the DNA construct expressing sH-3C3d had higher titers of anti-H antibodies compared to serum from mice vaccinated with DNA expressing sH only. In addition, sH-3C3d elicited higher neutralizing antibody titers that inhibited MV induced plaque formation.en-USimmunizationVaccinePatent